Elite Health Systems Inc. has announced the commencement of a private placement of its common stock, aiming to raise between $500,000 and $4 million. This strategic move reflects the company's ongoing efforts to enhance its operational activities, particularly for its subsidiary, Elite Health Plan, Inc., which focuses on providing Medicare Advantage plans for seniors.
The announcement was made on November 16, 2026, and the filing was submitted to the SEC on November 20, 2026. The private placement is set at a price of $0.60 per share. Notably, if the company raises at least $3 million through this offering, it will issue additional shares to previous investors who participated in a prior financing round at $0.95 per share.
Background
Elite Health Systems Inc. operates within the specialty outpatient facilities sector, classified under the SIC code 8093. The company is traded on the OTC exchange under the ticker symbol EHSI. Recent filings include a Form NT 10-Q on November 16, 2026, and a Form 4 on September 9, 2026, among others.
What the Filing Says
The filing states, "On November 16, 2026, the Board of Directors of Elite Health Systems Inc. announced the commencement of a private placement of shares of the Company’s common stock for expected gross proceeds of a minimum of $500,000 and up to a maximum of $4,000,000 at a price per share of $0.60." Furthermore, it mentions that the company will rely on exemptions from registration available under Section 4(a)(2) and/or Rule 506(b) of Regulation D of the Securities Act.
Impact
This private placement may significantly affect the company’s operational capabilities, especially for Elite Health Plan, Inc., which is currently enrolling members for its Medicare Advantage plan. As of November 18, 2026, the company reported that the Centers for Medicare & Medicaid Services had accepted 2,407 new member applications during the Annual Enrollment Period.
What's Next
The company plans to file a Form D with the SEC within 15 days of the first date of sale. An initial closing of the private placement is anticipated to occur within a month from the commencement date, with multiple closings expected thereafter.
This current report on Form 8-K is issued in accordance with Rule 135c under the Securities Act, and it is neither an offer to sell any securities nor a solicitation of an offer to buy, nor shall there be any sale of such securities in any state or jurisdiction where such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










